NCT06059664View on ClinicalTrials.gov

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Kidney Transplant; Complications
Interventions
DRUG

Finerenone Oral Tablet

Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.

DRUG

Placebo

Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.

Trial Locations (1)

27514

RECRUITING

UNC Eastowne Kidney Transplant Clinic, Chapel Hill

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER